Literature DB >> 8501330

Kinetics of serum and cellular interleukin-5 in posttreatment eosinophilia of patients with lymphatic filariasis.

A P Limaye1, E A Ottesen, V Kumaraswami, J S Abrams, J Regunathan, V Vijayasekaran, K Jayaraman, T B Nutman.   

Abstract

Peripheral blood eosinophil counts and serum levels and in vitro production of eosinophilopoietic cytokines were assessed before and at frequent intervals after diethylcarbamazine treatment of Bancroftian filariasis. Eosinophil counts peaked at day 7 after the start of treatment (359% +/- 118% of pretreatment levels) and declined to pretreatment levels by day 17. Serum interleukin (IL)-5, undetectable in 14 of 15 patients before treatment, rose sharply but transiently, with peak levels (32 +/- 7 pg/mL) 2 days after diethylcarbamazine treatment. Granulocyte-macrophage colony-stimulating factor and IL-3 were not detectable in serum at any time. In vitro mitogen-induced IL-5 levels decreased significantly in 7 of 9 patients 3 days after treatment when serum IL-5 was at near-peak levels. By day 10 IL-5 values increased in 8 of 9 patients compared with treatment values (P < .02). These data define the temporal relation between serum IL-5 levels and the subsequent development of eosinophilia and suggest that lymphocytes are the source of IL-5.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501330     DOI: 10.1093/infdis/167.6.1396

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel.

Authors:  Claus M Reimert; Colin M Fitzsimmons; Sarah Joseph; Joseph K Mwatha; Frances M Jones; Gachuhi Kimani; Karl F Hoffmann; Mark Booth; Narcis B Kabatereine; David W Dunne; Birgitte J Vennervald
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection.

Authors:  Jesica A Herrick; Fanny Legrand; Raceline Gounoue; Godwin Nchinda; Céline Montavon; Jean Bopda; Steve Mbickmen Tchana; Bienvenu Etogo Ondigui; Konrad Nguluwe; Michael P Fay; Michelle Makiya; Simon Metenou; Thomas B Nutman; Joseph Kamgno; Amy D Klion
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  Perturbations in eosinophil homeostasis following treatment of lymphatic filariasis.

Authors:  R Gopinath; L E Hanna; V Kumaraswami; V Perumal; V Kavitha; V Vijayasekaran; T B Nutman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

4.  A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.

Authors:  Fanny Legrand; Jesica Herrick; Michelle Makiya; Roshan Ramanathan; Reagan Thompson; Shakuntala Rampertaap; Jennifer Stoddard; JeanAnne Ware; Michael P Fay; Nicole Holland-Thomas; Thomas B Nutman; Amy D Klion
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

Review 5.  Eosinophils and helminth infection: protective or pathogenic?

Authors:  E Mitre; A D Klion
Journal:  Semin Immunopathol       Date:  2021-06-24       Impact factor: 9.623

6.  Elevated adaptive immune responses are associated with latent infections of Wuchereria bancrofti.

Authors:  Kathrin Arndts; Susanne Deininger; Sabine Specht; Ute Klarmann; Sabine Mand; Tomabu Adjobimey; Alexander Y Debrah; Linda Batsa; Alexander Kwarteng; Christian Epp; Mark Taylor; Ohene Adjei; Laura E Layland; Achim Hoerauf
Journal:  PLoS Negl Trop Dis       Date:  2012-04-03

7.  Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis.

Authors:  Britt J Andersen; Jessica Kumar; Kurt Curtis; Nelly Sanuku; Samson Satofan; Christopher L King; Peter U Fischer; Gary J Weil
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

8.  Chemotherapy for schistosomiasis in Ugandan fishermen: treatment can cause a rapid increase in interleukin-5 levels in plasma but decreased levels of eosinophilia and worm-specific immunoglobulin E.

Authors:  Colin M Fitzsimmons; Sarah Joseph; Frances M Jones; Claus M Reimert; Karl F Hoffmann; Francis Kazibwe; Gachuhi Kimani; Joseph K Mwatha; John H Ouma; Edridah M Tukahebwa; Henry C Kariuki; Birgitte J Vennervald; Narcis B Kabatereine; David W Dunne
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

9.  Rapidly boosted Plasma IL-5 induced by treatment of human Schistosomiasis haematobium is dependent on antigen dose, IgE and eosinophils.

Authors:  Shona Wilson; Frances M Jones; Hassan K M Fofana; Aissata Doucouré; Aly Landouré; Gachuhi Kimani; Joseph K Mwatha; Moussa Sacko; Birgitte J Vennervald; David W Dunne
Journal:  PLoS Negl Trop Dis       Date:  2013-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.